Mild Cognitive Impairment Clinical Trial
Official title:
Reshaping the Path Post Hip Fracture in Mild Cognitive Impairment
Verified date | April 2024 |
Source | University of British Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Hip fracture is recognized as one of the most serious consequences of osteoporosis, less than half regain pre-fracture independence. 95% of all hip fractures in older adults are due to falls. Thus, reducing fall risk while restoring function post-hip fracture is critical. Many with fall-related hip fractures have cognitive impairment; cognitive impairment increases the risk of falls. The purpose of this 6-month proof-of-concept randomized controlled trial (RCT) is to assess the efficacy of the home-based Otago Exercise Program (OEP) compared with usual care in reducing fall risk among older adults with mild cognitive impairment (MCI) and a fall-related hip fracture.
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | May 31, 2024 |
Est. primary completion date | May 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: 1) aged 65 or older; 2) sustained a fall-related hip fracture in the last 12 months and have returned home; 3) have preserved general cognition as indicated by a Mini-Mental State Examination (MMSE) score = or > 20/30; 4) have subjective memory complaints, determined by interview;22 5) score < 26/30 on the Montreal Cognitive Assessment (MoCA); 6) have an absence of significant functional impairment and no dementia as determined by a physician; 7) are not expected to start, or are stable (i.e., > 3 months) on a fixed dose of anti-dementia medications (e.g., donepezil, galantamine) during the RCT; 8) are expected to live > 12 months (based on the geriatricians' expert opinion); 9) can read, write, and speak English with acceptable visual and auditory acuity; 10) are able to walk 3 meters with or without an assistive device; and 1) provide written informed consent. Exclusion Criteria: 1) diagnosed with or suspected to have (by the geriatrician) a neurodegenerative disease (e.g., Parkinson's disease) or dementia; 2) had a clinical stroke; or 3) have a history indicative of carotid sinus sensitivity (i.e., syncopal falls). |
Country | Name | City | State |
---|---|---|---|
Canada | University of British Columbia | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia | Amgen |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Physiological Profile Assessment | A measure of fall risk (z-score). | Baseline to 6 Months | |
Secondary | Change in Short Physical Performance Battery | A measure of balance and mobility (out of 12 points). | Baseline to 3 Months and 6 Months | |
Secondary | Change in Usual Gait Speed | Gait speed over 4 meters (m/s). | Baseline to 3 Months and 6 Months | |
Secondary | Change in Life Space Assessment | Mobility within a life-space level. | Baseline to 3 Months and 6 Months | |
Secondary | Change in NIH Cognitive Toolbox | Cognitive performance of executive functions. | Baseline to 3 Months and 6 Months | |
Secondary | Change in Digit Symbol Substitute Test | Cognitive performance of processing speed. | Baseline to 3 Months and 6 Months | |
Secondary | Change in Center for Epidemiological Studies Depression Scale | Mood | Baseline to 3 Months and 6 Months | |
Secondary | Change in Positive and Negative Affect Scale | Mood | Baseline to 3 Months and 6 Months | |
Secondary | Change in EQ-5D-5L | Quality of Life | Baseline to 3 Months and 6 Months | |
Secondary | Change in ICE-CAP | Wellbeing | Baseline to 3 Months and 6 Months | |
Secondary | Change in Physical Activity for the Elderly | Physical activity over the last 7 days | Monthly from Baseline to 6 Months | |
Secondary | Total Number of Prospective Falls | Self-report of falls using calendars | Monthly from Baseline to 6 Months | |
Secondary | Change in Activities Specific Balance Confidence | Fall-related self efficacy | Baseline to 3 Months and 6 Months | |
Secondary | Change in Physiological Profile Assessment | A measure of fall risk (z-score); higher z scores indicate higher risk of falls. | Baseline to 3 Months | |
Secondary | Change in Timed Up and Go Test | A measure of functional mobility; greater time for completion indicate poorer performance. | Baseline to 3 Months and 6 Months | |
Secondary | Change in Fried Frailty | A measure of physical frailty | Baseline to 3 Months and 6 Months | |
Secondary | Change in Pittsburgh Sleep Quality Index | A measure of subjective sleep quality | Baseline to 3 Month and 6 Months | |
Secondary | Change in Rey Auditory Verbal Learning | A measure of episodic memory; higher scores indicate bettter episodic performance. | Baseline to 3 Month and 6 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |